`
`“—
`
`——
`
`Title of Invention:
`
`Buprenorphine Wafer For Drug Substitution Therapy
`
`
`
`——
`
`——
`
`Payment information:
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`——
`
`
`
`
`
`- a
`
`Document Descri
`
`tion
`
`p
`
`File Size(Bytes)/
`Message Digest
`937546
`
`Pages
`Multi
`Part /.zip (if appl.)
`
`Specification
`
`1861 _2 7000O6_Spec.pdf
`
`1a450d2d3d272bca1edf957338674e68e46
`808th
`
`Oath or Declaration filed
`
`1861_27000O6_Declarations.
`
`1287037
`
`117538
`
`Authorization for Extension of Time all
`.
`replles
`
`1861_2700006_Auth.pdf
`
`b84757e90c1c2f24c4c50c635945210457a I
`0f8c
`
`File Listing:
`
`Document
`Number
`
`.I
`
`a”.o qE W=- oE
`
`”.o qE W=- oE
`
`||||||||H||||||
`
`a”.c: .t53 W=- c:E!
`
`-
`
`a”.c: .t53 W=- c:E!
`
`-
`
`a”.c: .t53 W=- c:E!
`
`a”.c: .t53 W=- c:E!
`
`-
`
`-
`
`-
`
`TrackOne Request
`
`1861_27000O6_Track1.pdf
`
`Transmittal Letter
`
`1861 _27000O6_IDS.pdf
`
`111215
`
`801853619884303e66e06903c0d8e05c014
`83e81
`
`144392
`
`c453536f0b9132117453c737b7afd71208f4
`f3ca
`
`867039
`
`Information Disclosure Statement (IDS)
`Form (5308)
`
`1861_27000O6_st8.pdf
`
`723359466e714ab768b341ea61f2430d83e
`Zeac9
`
`
`
`This is not an USPTO supplied IDS fillable form
`
`1824188
`
`Application Data Sheet
`
`1861_27000O6_eADS.pdf
`
`8c0ceb1e51078323603e3c353718690c375‘
`36b2
`
`Transmittal of New Application
`
`1861_27000O6_utilitytransmitt
`aLpdf
`
`dce59fd51b920cf919645d96c2b31dc0c66
`b9c10
`
`176811
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`
`
`Claims
`
`1861_27000O6_claims.pdf
`
`de328ecc93b84ff6633318152102d33dedc'
`1321
`
`Fee Worksheet (SBO6)
`
`fee—info.pdf
`
`d81ee594dbbef40e9391337933213e3203e
`d562d
`
`Total Files Size (in bytes)
`
`5555679
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)—(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`